LC
MLTX icon

Lindbrook Capital’s MoonLake Immunotherapeutics MLTX Stock Holding History

Lindbrook Capital’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$156 Buy
+4
New +$172 ﹤0.01% 2719

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Lindbrook Capital's MLTX Position: Q1 2025 in Review

Lindbrook Capital opened a new position in MoonLake Immunotherapeutics (MLTX) in Q1 2025: 4 shares worth $156. The stake represents ﹤0.01% of the portfolio and ranks #2719 among its holdings.

136 funds tracked by Wall St. Rank hold MLTX as of Q1 2025.

  • Lindbrook Capital held 4 shares of MoonLake Immunotherapeutics worth $156 as of Q1 2025.
  • MoonLake Immunotherapeutics was a new Lindbrook Capital position in Q1 2025.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #2719 holding.
  • 136 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.